MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

On August 19, 2022 Medivir reported that (Press release, Medivir, AUG 19, 2022, View Source;interim-report-january–june-2022-301609058.html [SID1234618518])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical development of fostrox remains the focus

April – June

Financial summary for the quarter

Net turnover amounted to SEK 0.5 (0.9) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -21.5 (-17.1) million. Basic and diluted earnings per share amounted to SEK -0.42 (-0.31) and SEK -0.42 (-0.31) respectively.
Cash flow from operating activities amounted to SEK -17.6 (-21.9) million.
Cash and cash equivalents at the end of the period amounted to SEK 162.8 (247.8) million.
Significant events during the quarter

At Medivir’s AGM on May 5, Uli Hacksell, Lennart Hansson, Bengt Westermark and Yilmaz Mahshid were re-elected and Anette Lindqvist was newly elected as board members in the company. Uli Hacksell was re-elected as chairman of the board. An van Es Johansson had declined re-election.
January – June

Financial summary for the period

Net turnover amounted to SEK 1.0 (10.8) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -52.9
(-24.3) million. Basic and diluted earnings per share amounted to SEK -1.00 (-0.51) and SEK -1.00 (-0.51) respectively.
Cash flow from operating activities amounted to SEK -57.5 (-23.3) million.
Cash and cash equivalents at the end of the period amounted to SEK 162.8 (247.8) million.
Significant events after the period

Fostroxacitabinebralpamide – the name given to MIV-818 by the World Health Organization (WHO) – received formal approval as a pharmaceutical name in the USA by the United States Adopted Names (USAN) Council.
Conference call for investors, analysts and the media

The Interim Report January – June 2022 will be presented by Medivir’s CEO, Jens Lindberg.